Illumina (NASDAQ:ILMN) Stock Moved Down to Hold by Wall Street Zen

Wall Street Zen downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

A number of other analysts have also weighed in on ILMN. Evercore reiterated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. JPMorgan Chase & Co. boosted their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. TD Cowen upped their price target on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Finally, Argus increased their price objective on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $214.69.

Illumina Stock Up 2.8%

Shares of NASDAQ ILMN opened at $273.04 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina has a 52 week low of $88.00 and a 52 week high of $280.17. The firm’s fifty day moving average is $219.37 and its 200 day moving average is $175.55. The company has a market cap of $41.23 billion, a price-to-earnings ratio of 50.94, a PEG ratio of 3.87 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Illumina will post 5.36 earnings per share for the current year.

Insider Transactions at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,061,850 shares of company stock worth $436,479,102 in the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Illumina during the second quarter valued at approximately $3,374,423,000. Capital World Investors grew its stake in Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the period. WCM Investment Management LLC raised its holdings in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA bought a new position in Illumina in the second quarter worth $617,981,000. Finally, Jupiter Topco LLC purchased a new position in Illumina during the second quarter valued at $358,652,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.